The move bolsters the CDMO’s commitment to cell and gene therapy by incorporating advanced manufacturing and fill-finish ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement ...

As the adoption of biologics rises, demand for home healthcare grows, and conditions like diabetes and autoimmune disorders ...

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies ...

Kapil Raina, MD, Principal of Market Access at Herspiegel Consulting, talks about disconnects in the industry, how patients have easier access to healthcare information, and the exciting future of ...

Rob Truckenmiller, CEO of PharmaCord, talks about the company’s role in patient services, trends he sees shaping patient access to healthcare in the U.S., and a recent patient-centric merger.

Tiara Green, president, Accessia Health, explains how empowering trusted local leaders and involving communities early are ...

The afternoon of day 2 at Asembia’s AXS25 Summit offered various intriguing sessions to pick from, including one on ...

A multi-national study reveals over half of older adults in several European countries are prescribed five or more ...

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

Will Pih, co-founder, Two Labs, explains how specialty pharmacies and manufacturers are adapting to financial pressures in rare disease care through patient-centric services, hub innovation, and ...